ClinicalTrials.gg
CompletedNCT05470920Updated Oct 2, 2026

Genetic Testing Decision Aid

An interventional study of Electronic Decision Aid and Pre-Test Genetic Counseling in Epithelial Ovarian Carcinoma and Pancreas Adenocarcinoma, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Health services research

How we know

Updated Oct 2, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 28 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Enrollment
36th of 381
297 · median 35
Started
2022
with 17 others
No phase
44 of 500
3 open now
Registered
468th of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 36th largest by enrollment of the 381 interventional ones that give a count, is one of 18 that started in 2022, is one of 44 with no phase, and was the 468th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

28 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 49 (65%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer

Read the detailed description

The research study procedures include: screening for eligibility and study questionnaires that would be performed in conjunction with either the genetic counselor visit or use of the electronic decision aid. The study questionnaires include:

  • Knowledge Survey
  • Shared Decision Making Process Survey
  • Decisional Conflict Scale

The research study will last up to 2 weeks. It is expected that about 350 people will take part in this research study.

The National Cancer Institute (NCI) is supporting this research study by providing funding for the research

03

Conditions studied

  • Epithelial Ovarian Carcinoma
  • Pancreas Adenocarcinoma

Keywords

  • pancreas adenocarcinoma.
  • epithelial ovarian carcinoma
  • decision aid
  • inherited cancer syndrome
  • genetic testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Being seen in clinic at Massachusetts General Hospital or Boston Medical Center
  • Diagnosed with malignant epithelial ovarian carcinoma or malignant pancreatic adenocarcinoma.

Exclusion criteria

Exclusion Criteria :

  • Unable or unwilling to provide , undergo randomization, or complete the surveys associated with the study
  • Previous germline genetic testing
  • History of hereditary pancreatitis
  • Members of the following vulnerable populations: adults unable to consent, individuals who are not yet adults
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
297 participants (actual)

Study arms

  • Experimental
    Electronic decision aid arm

    Receive decision aid followed by an appointment with their oncologist.

    Behavioral: Electronic Decision Aid

  • Active comparator
    Genetic counselor Arm

    Receive pretest counseling with a genetic counselor.

    Behavioral: Pre-Test Genetic Counseling

Interventions

  • BehavioralElectronic Decision Aid

    Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires

  • BehavioralPre-Test Genetic Counseling

    Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires

06

What researchers measure

Primary outcomes

  1. Decisional Conflict Scores

    The decisional conflict score is a score ranging from 0-100 that is measured from a 10-question validated decisional conflict scale. The scale assesses participant's confidence in their decision with higher scores indicating higher decisional conflict.

    Time frame: 1 week after genetics session

  2. Average change in knowledge survey score

    Average change in score on a 10-question knowledge survey to assess basic information about genetics and genetic testing that was covered in their appointment. Scores on the scale range from 0-10. Higher values in the change in knowledge survey score suggest greater amount of knowledge gained in the genetics session.

    Time frame: baseline (prior to participant completing either genetics sessions) to 1-week following session, approximately 2 weeks

  3. Shared Decision Making Process Scores

    The shared decision making process score is a score on a scale of 1-4 based on responses on a validated 4-item shared-decision making scale. The scale assesses how well the decision aid/oncology provider, or the genetic counselor engaged in shared decision-making as perceived by the subject. Higher scores on this scale indicate more shared decision making.

    Time frame: 1 week after genetics session

Secondary outcomes

  1. Average time between genetic testing recommendation and sample collection

    Difference between the two study arms in the time it takes between participants being recommended for genetic testing and a sample being collected.

    Time frame: Initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months

  2. Average Duration of Decision Making Process

    Amount of time patients spend learning and making a decision about genetic testing in both arms of the study.

    Time frame: Approximately 30 minutes - 1 hour

  3. Ratio of the number of participants who chose each of the three panels offered

    Ratios of participants who choose the small, intermediate, and broad testing panel in both arms of the study.

    Time frame: At the conclusion of genetics session (day 1)

  4. Percentage of participants choosing genetic testing

    Percentage of participants in each arm of the study who choose to get genetic testing after the educational intervention

    Time frame: At the conclusion of genetics session (day 1)

07

Study locations

2 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
  • Mass General at North Shore Cancer Center
    Danvers, Massachusetts 01923, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2026, 43 months.

Of 30 interventional studies with no phase under Carcinoma, Ovarian Epithelial, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 93. This study's 43 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → May 2026 and completion Dec 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2022
First posted
Jul 22, 2022
StartActual
Oct 14, 2022
Primary completionActual
May 19, 2026was Sep 2026
CompletionActual
May 19, 2026was Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 2, 2026
Primary completion
Sep 30, 2026→May 19, 2026 (actual)
Oct 2, 2026
Study completion
Dec 31, 2026→May 19, 2026 (actual)
Oct 2, 2026
Enrollment
350 (estimated)→297 (actual)
Oct 2, 2026
Documents
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Sep 30, 2026→May 19, 2026 (now actual)
    Study completion Dec 31, 2026→May 19, 2026 (now actual)
    Enrollment 350 (estimated)→297 (actual)
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05470920
Responsible party
Daniel C Chung (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jul 22, 2022
Start date
Oct 14, 2022
Primary completion
May 19, 2026
Completion
May 19, 2026
Last update
Oct 2, 2026

Study contacts

Daniel C. Chung, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion